Get startedLog in
    Picture of Can Fite Biopharma logo

    CANF — Can Fite Biopharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMicro CapSucker Stock
    All News

    Brief: Can-Fite Says It Has Raised $175 Million To Date For Development Of Namodenoson And Piclidenoson

    Picture of Can Fite Biopharma logoCan Fite Biopharma
    05/05/2025 13:40
    May 5 (Reuters) - Can Fite Biopharma Ltd CANF.TA:

CAN-FITE HAS RAISED $175 MILLION IN TOTAL TO DATE FOR THE DEVELOPMENT OF NAMODENOSON AND PICLIDENOSON, ADVANCING INTO PIVOTAL PHASE 3 TRIALS IN LIVER CANCER AND PSORIASIS

Source text: ID:nGNXbMq5z4

Further company coverage: CANF.TA

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Can Fite Biopharma

    See all news